MAPT and Alzheimer disease: A collection of histopathological, imaging, metabolic, and molecular markers characterize AD, including cerebral cortical and subcortical atrophy, neuronal loss, synaptic terminal damages, microvascular damages, different inflammatory reactions including reactive astrocytosis, and significantly hyperphosphorylated Tau and increased amyloid beta (Aβ) deposits (8).